AGE - AgeX Therapeutics, Inc.

Company Profile

AgeX Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Alameda, California and currently employs 12 full-time employees. The firm is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.